

Title (en)
USES OF ANTI-ICOS ANTIBODIES

Title (de)
VERWENDUNGEN VON ANTI-ICOS-ANTIKÖRPERN

Title (fr)
UTILISATIONS D'ANTICORPS ANTI-ICOS

Publication
EP 4340943 A1 20240327 (EN)

Application
EP 22731078 A 20220518

Priority
• US 202163190016 P 20210518
• EP 2022063450 W 20220518

Abstract (en)
[origin: AU2022276349A1] Therapeutic use and dosing regimen of anti-ICOS antibodies or antigen-binding fragments thereof for modulating the ratio between regulatory T cells and effector T cells, stimulating the immune system of patients, and/or treating tumours or cancers, as monotherapy or combination therapy, e.g., with anti-PD-L1 antibodies or antigen-binding fragments thereof.

IPC 8 full level
A61P 35/00 (2006.01); **A61K 39/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP IL KR)
A61P 35/00 (2017.12 - EP IL KR); **C07K 16/2818** (2013.01 - EP IL KR); **C07K 16/2827** (2013.01 - EP IL KR); **A61K 2039/505** (2013.01 - EP IL); **A61K 2039/507** (2013.01 - EP IL KR); **A61K 2039/545** (2013.01 - EP IL KR); **A61K 2039/57** (2013.01 - EP IL KR); **C07K 2317/74** (2013.01 - EP IL KR); **C07K 2317/75** (2013.01 - EP IL KR); **C07K 2317/76** (2013.01 - EP IL KR)

Citation (search report)
See references of WO 2022243378A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
KH MA MD TN

DOCDB simple family (publication)
AU 2022276349 A1 20240104; CN 117460529 A 20240126; EP 4340943 A1 20240327; IL 308603 A 20240101; JP 2024518843 A 20240507; KR 20240007760 A 20240116

DOCDB simple family (application)
AU 2022276349 A 20220518; CN 202280036196 A 20220518; EP 22731078 A 20220518; IL 30860323 A 20231116; JP 2023571502 A 20220518; KR 20237043292 A 20220518